Physician profile
Rafael Lao
NPI 1265477053
$1,948.02
in general payments reported to CMS, 2019-2025
16 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.05 · 2020: $167 · 2021: $144 · 2022: $333 · 2023: $407 · 2024: $359 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190 · Education: $83.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.89 |
| Education | $83.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $398.36 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $334.48 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $284.74 | 2022-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $262.57 | 2020-2023 | Korsuva, Veltassa |
| Mallinckrodt Hospital Products INC. | $146.48 | 2025 | Acthar |
| Amgen INC. | $112.98 | 2019-2025 | Tavneos |
| Ardelyx, INC. | $98.05 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.81 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $59.84 | 2023-2024 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $41.50 | 2023 | Gattex |
| Chiesi USA, INC. | $30.75 | 2025 | Elfabrio |
| Fresenius USA Marketing, INC. | $30.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.20 | 2023 | |
| Kyowa Kirin, INC. | $17.95 | 2023 | Crysvita |
| Apellis Pharmaceuticals, INC. | $16.71 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.23 | 2023 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Lao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.